{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:22:45Z","timestamp":1791296565453,"version":"4.1.0"},"reference-count":17,"publisher":"BMJ","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pathol"],"published-print":{"date-parts":[[2009,9]]},"abstract":"\n Background:<\/jats:title>\n \n Chronic myelomonocytic leukaemia (CMML) is a haematopoietic malignancy with heterogeneous clinical and morphological features. It is classified in the World Health Organization myeloproliferative-myelodysplastic overlap category. JAK2\n V617F<\/jats:sup>\n mutation can be found in a large percentage of patients with myeloproliferative neoplasms.\n <\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n \n To investigate the association between JAK2\n V617F<\/jats:sup>\n mutation and clinical, haematological and bone marrow histological features in CMML and to verify whether the mutation is associated with the myeloproliferative type of the disease.\n <\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n \n 78 consecutive patients with newly diagnosed CMML from 2004 to 2008 were included in the study. JAK2\n V617F<\/jats:sup>\n mutation was assessed using direct sequencing of exon 14 or by allele-specific PCR from total peripheral blood or bone marrow samples.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n JAK2\n V617F<\/jats:sup>\n mutation was identified in eight cases (10.2%). All patients with the mutation presented with splenomegaly and had a significantly higher haemoglobin level and neutrophil count than patients without the mutation. All bone marrow biopsies of JAK2\n V617F<\/jats:sup>\n -mutated CMML showed increased erythropoiesis, a marked myeloid and megakaryocytic hyperplasia with occasionally clustered megakaryocytes, and a mild or moderate (grade 1 or 2) fibrosis; six cases showed an increased number of dilated sinusoids and reactive lymphoid nodules.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n \n The results indicate that JAK2\n V617F<\/jats:sup>\n mutation is associated with clinical and morphological features of the myeloproliferative type of CMML. Therefore, JAK2 mutation analysis together with bone marrow morphology could help in a more appropriate classification of the disease.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/jcp.2009.065904","type":"journal-article","created":{"date-parts":[[2009,9,4]],"date-time":"2009-09-04T15:32:48Z","timestamp":1252078368000},"page":"798-801","source":"Crossref","is-referenced-by-count":42,"title":["JAK2\n V617F<\/sup>\n activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia"],"prefix":"10.1136","volume":"62","author":[{"given":"A","family":"Pich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Sismondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Godio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Davico","family":"Bonino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Marmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Francia","family":"di Celle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2009,9,4]]},"reference":[{"key":"2025092509093244000_62.9.798.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00021-8"},{"key":"2025092509093244000_62.9.798.2","first-page":"202","article-title":"CMML: a biologically distinct myeloproliferative disease.","volume":"2","author":"Cortes","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"2025092509093244000_62.9.798.3","first-page":"218","article-title":"Chronic myelomonocytic leukemia: myeloproliferative variant.","volume":"3","author":"Onida","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"2025092509093244000_62.9.798.4","unstructured":"Orazi A Bennett JM Germing U Chronic myelomonocytic leukaemia.In: Swerdlow S H Campo E Harris N L , eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon: IARC Press, 2008:75\u00e2\u0080\u00939."},{"key":"2025092509093244000_62.9.798.5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2025092509093244000_62.9.798.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"2025092509093244000_62.9.798.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"2025092509093244000_62.9.798.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"2025092509093244000_62.9.798.9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12337"},{"key":"2025092509093244000_62.9.798.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1898"},{"key":"2025092509093244000_62.9.798.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1800"},{"key":"2025092509093244000_62.9.798.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1183"},{"key":"2025092509093244000_62.9.798.13","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity.","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"2025092509093244000_62.9.798.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02119.x"},{"key":"2025092509093244000_62.9.798.15","doi-asserted-by":"publisher","DOI":"10.1038\/sj\/leu\/2401592"},{"key":"2025092509093244000_62.9.798.16","unstructured":"Dixon WJ Brown MG Engelman L . BMPD statistical software manual. Berkeley, CA: University of California Press, 1990."},{"key":"2025092509093244000_62.9.798.17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0145-2126(00)00159-4","article-title":"Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukaemia\u00e2\u0080\u0094distinct subgroups or two stages of the same disease?","volume":"5","author":"Voglov\u00c3\u00a1","year":"2001","journal-title":"Leuk Res"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jcp.2009.065904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:09:40Z","timestamp":1758816580000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jcp.2009.065904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,9,4]]},"published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1136\/jcp.2009.065904"],"URL":"https:\/\/doi.org\/10.1136\/jcp.2009.065904","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}